Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

Pfizer PFE is due to report second-quarter results on Aug. 5. All eyes will be on sales of Pfizer’s oncology drugs, which ...

The investment will fund a new drug manufacturing facility in Virginia, and expand research and development in at least 5 ...

Lee, at this point in the year, all the companies that pay dividends have pretty much set their dividends. You know, the ...

Brentuximab vedotin combined with cyclophosphamide, doxorubicin, and prednisone (CHP) shows promising results as a first-line ...

The second healthcare sector IPCEI – approving up to €403 million of State aid by five Member States, including France, ...

More than 30 years ago, when Jean-Pascal Tricoire first came to China, his friends gave him the Chinese ...

Emerging therapies, including antibody-drug conjugates and biomarker-driven approaches, have the potential to significantly ...

DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology Approval represents critical advancement ...

WASHINGTON] Crypto companies and advocates of digital assets boosted their lobbying this year to ensure passage of landmark ...

Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) ('Ascentage Pharma” or the 'Company”), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, ...